Nerve-Saving gastric bypass may cut ulcer risk
NCT ID NCT05357443
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether keeping the vagus nerve intact during gastric bypass surgery can lower the chance of developing painful ulcers. Researchers will measure a hormone called gastrin in 50 adults before and after surgery. The goal is to understand how nerve preservation affects ulcer formation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
50 people
The number who actually took part.
- Started
-
Aug 2022
- Expected to finish
-
Sep 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18 years and older * Diagnosis of obesity or disorder of metabolism undergoing routine gastric bypass surgical intervention * Capable of giving signed informed consent. Exclusion Criteria: * Under 18 years of age * Ineligible for gastric bypass surgery * Pregnant women or women actively seeking to become pregnant.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Gastric bypass are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sanford Health
Fargo, North Dakota, 58102, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A multicenter, randomized, Active-Controlled, Open-Label phase IIb study evaluating safety and tolerability of switching to zovaglutide injection after titration to 2.4 mg semaglutide injection (Wegovy®) in adults with obesity (HORIZON-SWITCH-SZ)
- Gonadotropin-releasing hormone agonist (GnRHa) plus letrozole in obese progestin-insensitive early-stage endometrial cancer patients with conservative treatment
- Safety and feasibility of the ENDOPLY system in humans: a pilot study
- Dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like Peptide-1 (GLP-1) receptor agonist in women with obesity for frozen embryo transfer (FET): pragmatic, multicenter, randomized controlled trial
- Effects of very low calorie ketogenic diet on microbiota, adipose tissue and immunitary regulation: pilot study on patients with metabolic syndrome
- Susceptibility to infectious diseases in obesity: an endocrine, translational, sociological evaluation